These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half. Pallarito K Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390 [No Abstract] [Full Text] [Related]
30. Biotech's wellspring: the health of private biotech in 2012. Huggett B Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390 [No Abstract] [Full Text] [Related]
31. My worst biotech investment. Jacobs T Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718 [No Abstract] [Full Text] [Related]
32. Another clue to biotech value. Jacobs T Nat Biotechnol; 2003 Jul; 21(7):746. PubMed ID: 12833091 [No Abstract] [Full Text] [Related]
33. Companies jostle for access to public markets. Bouchie A Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309 [No Abstract] [Full Text] [Related]
34. Other ways of financing your company. Aldag J; Kessel M; Ibrahim A; Hill R; McCubbin P Nat Biotechnol; 2008 Feb; 26(2):155-7. PubMed ID: 18273945 [TBL] [Abstract][Full Text] [Related]
35. IPOs: the narrow window closes? Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641 [No Abstract] [Full Text] [Related]
40. Looking at US versus European exit opportunities. Lawrence S Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]